LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E. Olson and colleagues. It acts as a moderately selective serotonin receptor agonist, primarily at the serotonin 5-HT2A receptor, though its activity at other subtypes such as the 5-HT2B and 5-HT2C receptors, and at other targets of LSD such as dopamine receptors, has not been published. It was developed in the course of resarch into non-hallucinogenic psychoplastogens, and is described as having around 24x lower potency than LSD and with "reduced hallucinogenic potential", though this would suggest it may still be of a similar potency to many psychedelic tryptamine derivatives. It has been researched for therapeutic applications including as a potential antidepressant. LSD-Quinoline was first described in the scientific literature by 2026.
See also Substituted lysergamide § Related compounds JRT (drug) Mefloquine
References